Researchers from the United States showed that treatment with the help of an immunomodulator interferon beta-1a does not improve the condition of patients with coronavirus infection. Moreover, its use leads to an increase in the number of complications in patients who require artificial ventilation of the lungs (IVL). Dedicated to the effectiveness of interferon treatment. Article of specialists is published in the magazine The Lancet Respiratory Medicine.
Interferon beta-1a is one of the most common preparations for the treatment of multiple sclerosis – the same sequence of amino acids, as well as the protein interferon beta, which is included in the group of interferon type I – generated by the human immune system to combat pathogens. Incable COVID-19 suppresses the development of interferons.
969 people from 63 hospitals of the United States, Mexico, Japan, Singapore and South Korea took part during clinical research Actt-3. The research participants were divided into two groups: one was given a combination of interferon beta-1a and the antiviral drug Redemevir, and the other is only Remedevir. The latter was used as an active control after it was found that it was more useful than placebo to reduce the recovery time after COVID-19.
Heads led by specialists from the National Institute of Allergy and Infectious Diseases of National Health Institutes of USA found that the combination of Inteferon and Redemevir did not bring clinical benefits. The time after which the patient began to recover both experimental and the control groups amounted to five days. The probability of improving the state for the fifteenth day of treatment was the same in both groups.
Moreover, researchers had to stop a set of participants with a severe COVID-19 participants who demanded high-strength oxygen therapy and exclude participants with IVL. It turned out that such people the reception of Interferon increases the risk of complications and severe outcomes of coronavirus infection. According to scientists, this is due to the fact that interferon strengthens the inflammatory response.